CD31 staining of the HCC17-0211 tumour treated with infigratinib and the combination of infigratinib and varlitinib showed evidence of intra-tumoral blood vessel remodelling, where blood vessels appear more ‘normalised’, with capillary-like structures, compared with the dysregulated blood vessels in the vehicle and varlitinib-treated tumours. This evidence concerns the gene PECAM1 and neoplasm.